Clinical trial · Interventional
LifeChamps Feasibility Study
LIFECHAMPS: A Collective Intelligence Platform to Support Cancer Champions - Stockholm Pilot Use Case 2
NCT05990634CI-TRIAL-00068765unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect data from various sources (PROM / PREM, sensors, journal data) to train AI based models in the LifeChamps digital platform in a pre-pilot, as well as partly implement a pilot/feasibility study to examine the applicability of the digital technology developed in LifeChamps, as well as the usability for patients (cancer survivors) and health care professionals
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LifeChamps Platform | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- LifeChamps Platform
- description
- Participants will be asked to use the LifeChamps platform and will be provided with the study equipment (sensors/home kit).
- interventionNames
- Device: LifeChamps Platform
Primary outcomes (2)
- measure
- Analytical models
- timeFrame
- 3 to 6 Months
- description
- The collected data will be used to train and test the analytical models. For example, the initial data from sensors will be refined, further, with statistical, spectral and supervised learning analyses to identify and extract possible patterns (e.g., activities of daily living) inside their signals. Sensor, EHR and PROM data will be all analysed together through exploratory algorithms (e.g., pairwise Markov random fields, Bayesian networks) to identify possible interactions and dependencies among their trajectories, mapping the frailty and QOL domains of elderly melanoma cancer patients across all the data collection process.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with malignant melanoma (stage I-III) and undergone primary treatment within the last 36 months. * Has completed primary and secondary cancer treatment and is now in remission (survivorship stage). * Assessed as physically and mentally able to participate in the study * Can read, write and understand the Swedish language * Can bring and use their own smart phone (Android version 10 or newer) below the study * Have 24-hour access to internet (broadband) via WiFi router in your own household and/or free 4G mobile data (sim card and 4G router will be provided if this criterion is not met) Exclusion Criteria: * Terminal cancer stage or prognosis \<18 months from time of recruitment * Diagnosed with severe mental illness or cognitive illness that affects the ability to participate * Screening with Mini-Cog where the result is between 0-2 * Inability or unwillingness to provide written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.